Free Newsletter
Emergent inks $29.7M anthrax vax contract
Emergent BioSolutions has inked a three-year, $29.7 million deal with Biomedical Advanced Research and Development Authority (BARDA) and the National Institute of Allergy and Infectious Diseases (NIAID). BARDA/NIAID will fund the further development of AV7909, a an anthrax vaccine candidate. AV7909 is made up of Emergent's own BioThrax and CPG 7909 (VaxImmune), which it licensed from Pfizer.
The three-year contract provides up to $24.9 million of funding for manufacturing of clinical lots, for non-clinical safety and efficacy studies, and for stability studies to further demonstrate that the vaccine candidate does not need refrigeration during storage, a key requirement of this vaccine development initiative. In addition, the contract provides up to $4.8 million for a Phase I clinical trial, to be funded as an option that, if exercised, would increase the value of the contract to $29.7 million.
- see Emergent's release
Related Articles:
Emergent wins $24M anthrax contract
Emergent accuses biotech execs of wrecking buyout pact
VaxGen sells anthrax vaccine to Emergent
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
